menu

The Multiple Faces of ATTRv-PN

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Heads Up: It Might Be ATTRv Polyneuropathy – A Microlearning Course on Diagnosis and Treatment

The Multiple Faces of ATTRv-PN

MinuteCE®
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Comments
  • Overview

    Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN treatment. Join the experts and equip yourself to effectively manage this challenging disease and improve patient outcomes. 

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    John L. Berk, MD
    Associate Professor of Medicine
    Director, Clinical Trials for Familial Amyloidosis
    Director, Localized Amyloid Clinic
    Chobanian & Avedisian School of Medicine: Amyloidosis Center
    Boston University
    Boston, MA

    Dr. Berk has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: AstraZeneca, Intellia
    Research: Alnylam, AstraZeneca, BridgeBio, Ionis
    Royalties: Merck, UpToDate

    Noel Dasgupta, MD, FACC
    Associate Professor of Clinical Medicine and Pathology & Laboratory Medicine
    Krannert Institute of Cardiology
    Indiana University
    Indianapolis, IN

    Dr. Dasgupta has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Consulting Fees: Alnylam, AstraZeneca, BridgeBio, Novo Nordisk  
    Research: Alexion, Alnylam, Eidos, Intellia, Ionis  

    Sami Khella, MD
    Professor of Neurology
    Penn Presbyterian Medical Center
    Department of Neurology
    University of Pennsylvania School of Medicine
    Philadelphia, PA

    Dr. Khella has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Alnylam, Alexion, AstraZeneca, Ionis, Pfizer

    Marcia Waddington-Cruz, MD, PhD
    Neurologist
    National Amyloidosis Referral Center
    Federal University of Rio de Janeiro
    Rio de Janeiro, Brazil

    Dr. Waddington-Cruz has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Alnylam, AstraZeneca, Ionis, Pfizer, PTC
    Research: Alnylam, Ionis

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Howard Green has nothing to disclose.
    • Andrea Mathis has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Colleen Resnick has nothing to disclose.
    • Susan Smith, MN, PhD, has ownership interest in Hepion Pharmaceuticals.
    • Mario Trucillo, PhD, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Differentiate between wild-type vs hereditary amyloid transthyretin (ATTR)
    • Determine the necessary information to make a diagnosis of hereditary ATTR polyneuropathy (ATTRv-PN)
    • Differentiate the relative safety profiles of disease-modifying therapies approved for ATTRv-PN
    • Interpret data from phase 3 clinical trials of therapies being investigated for the treatment of ATTRv-PN 
  • Target Audience

    This activity is designed to meet the educational needs of neurologists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until April 23, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by an independent educational grant from AstraZeneca.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule24 May 2024